GlobeNewswire by notified

Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements

Share

LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms 10-Q for the quarters ending September 30, 2022 and December 31, 2022 on March 7th and March 9th, 2023, respectively. 

“I am very pleased that the Company is once again compliant with the NASDAQ listing requirements. We have turned another page towards a promising future,” said Gregg Alton, former long-time General Counsel and Chief Compliance Officer and, later, Interim CEO of Gilead Sciences, and Lead Independent Board Member of Enochian BioSciences.

Dr. Mark Dybul, CEO of the Company, said, “Returning to full compliance is a significant accomplishment. Despite challenges, the science remains strong and encouraging. I look forward to the Company advancing its novel technology to possibly treat several solid tumors with relatively poor life expectancy from pre-clinical to clinical phase potentially by early 2024.”

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Source: Enochian Biosciences Inc.


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Proposals to the Annual General Meeting of Municipality Finance Plc26.4.2024 10:00:00 CEST | Press release

Municipality Finance Plc Stock Exchange Release 26 April 2024 at 11:00 am (EEST) Proposals to the Annual General Meeting of Municipality Finance Plc Municipality Finance Plc’s (hereinafter MuniFin) Board of Directors (the Board) and the Shareholders’ Nomination Committee (the Nomination Committee) have made the following proposals to the Annual General Meeting (the AGM) convening on 17 May 2024 at 10:00 (EET): Use of profit shown on the balance sheet and the distribution of dividend MuniFin has distributable funds of EUR 365,610,693.66 of which the profit for the financial year totaled EUR 67,416,447.86. In accordance with the dividend policy adopted by the AGM in March 2023, MuniFin’s aim is to pay 30-60% of the Group’s financial year’s profit in dividends. The Board proposes to the AGM that a dividend of EUR 1.69 per share, totaling EUR 66,017,818.62 shall be distributed based on the balance sheet to be adopted for 2023. MuniFin’s profit for the financial year is strong. The Board co

Meddelelse nr. 07/2023: Delårsrapport 1. januar – 31. marts 202426.4.2024 09:57:33 CEST | pressemeddelelse

Bestyrelsen for Strategic Investments A/S har på et møde d.d. behandlet selskabets delårsrapport for perioden 1. januar – 31. marts 2024. Resumé: Strategic Investments resultat for 1. kvartal 2024 blev på DKK -70,4m før og efter skat, svarende til et afkast på -14,5%.Bag det negative resultat ligger en generel negativ udvikling for small cap aktier og en negativ kursudvikling på tværs af selskabets aktieportefølje, der primært indeholder small cap aktier.Selskabets egenkapital var d. 31. marts 2024 DKK 416,7m, svarende til en indre værdi af selskabets aktier på DKK 1,05 pr. aktie. Bestyrelsen har, i overensstemmelse med selskabets udbyttepolitik, indstillet udbetaling af et udbytte på DKK 0,02 på selskabets generalforsamling d.d.Strategic Investments forventer for 2024 uændret et resultat, der lever op til selskabets langsigtede målsætning om over tid at skabe et årligt afkast på 10-15%, svarende til et resultat for 2024 på DKK 47-73m. Spørgsmål vedrørende denne meddelelse kan rettes t

HSBC Continental Europe: Post Stabilisation Notice26.4.2024 09:30:00 CEST | Press release

ASR Nederland N.V. Post Stabilisation Notice PARIS, April 26, 2024 (GLOBE NEWSWIRE) -- HSBC (contact: syndexecution@noexternalmail.hsbc.com) hereby gives notice that no stabilisation was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer:ASR Nederland N.V.Guarantor (if any):naAggregate nominal amount:EUR 500,000,000Description:6.625% due PerpetualNC8.25yrOffer price:100Stabilising Manager:HSBC Continental Europe This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further informat

HiddenA line styled icon from Orion Icon Library.Eye